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Abundant evidence has accumulated indicating that neoplasms  induced by 
various oncogenic viruses possess specific transplantation antigens (for review 
see reference  1),  common for different tumors induced by the same virus.  In 
analogy with results obtained in experiments  with other viral tumors, a strong 
resistance  against  isotransplantation  of  mouse  sarcomas,  induced  by  the 
Schmidt-Ruppin strain of Rous sarcoma virus (RSV-SR),  can be built up by 
pretreatment with allogeneic or syngeneic Rous sarcoma cells (2, 3). However, 
in contrast to the other viral tumor systems, attempts to demonstrate a virus- 
induced transplantation resistance  (VIR)  after inoculation of RSV-SR  into 
adult mice have given negative or inconclusive results (3). 
Inoculation of newborn mice with RSV-SR  (in the form of a suspension of 
Rous chicken sarcoma ceils) results in the development of primary sarcomas in 
20 to 70 % of the animals, most of them appearing within 2 months (4). Inocula- 
tion of RSV-SR into adult mice has hitherto failed to induce sarcomas, even if 
the  animals are  preirradiated  (400 R  whole  body X-irradiation  24  hr  pre- 
viously). These findings indicate a  similar  immunological  mechanism as has 
been proposed for the polyoma system (5, 6), viz., the successful immunization 
of adult, immunologically  competent animals against the foreign antigens of 
infected and/or transformed cells and the subsequent rejection of these ceils. 
That tumors sometimes do develop after virus inoculation into newborn mice 
might be due to the induction of tolerance to these foreign antigens in immuno- 
logically immature animals.  However,  in hamsters the induction of primary 
SV40 tumors seems to occur in the absence of immunological  tolerance,  and 
hamsters beating primary tumors are  resistant in transplantation tests  (7). 
Other possible mechanisms include immunological enhancement of the primary 
tumor growth or growth despite a certain degree of immunization. 
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Further  experiments  seemed  desirable  in  order  to  elucidate  the  immuno- 
logical events in the  course of induction  of primary Rous sarcomas  in mice. 
Preliminary studies have indicated  that the newborn infected mice which do 
not develop primary Rous sarcomas exhibit a specific transplantation immunity 
to Rous  sarcoma isografts  (8).  The  present paper  fully confirms this  result. 
Furthermore  the  studies  have  been  extended  to  the  mice  which do  develop 
primary tumors. The results of parallel investigations  on specific transplanta- 
tion immunity  and development  of virus-neutralizing  humoral antibodies  are 
reported. 
Material and Methods 
Mice.--The inbred strains A/Sn, its coisogenic resistant sublines A.CA and A.SW, as well 
as C3H and Fl-hybrids between these strains and DBA/2, CBA, and C57BL/K1 were used. 
The breeding and maintenance of the animals have been described previously (3, 6). 
Tumor Induction.--For induction of primary tumors newborn mice, not older than 2 days, 
were injected subcutaneously with 0.05 cc of a crude cell suspension of Rous chicken sarcoma 
(strain RSV-SR) prepared (1:5) in a balanced salt solution (4). It was attempted to localize 
the inocula to the proximal part of the right hind leg in order to obtain tumors at an operable 
site. 
When suitably located primary tumors had reached a  diameter of 5 to 10 mm, they were 
extirpated under ether anesthesia, either by amputation of the tumor-bearing leg or by direct 
excision of tumors on the back, that could be loosened from the spine and back muscles. 
Sham operations on syngeneic control mice were performed in parallel either by amputa- 
tion of a leg or by an incision on the back. Mice developing no palpable primary tumors after 
inoculation of RSV-SR when newborn were used in the transplantation tests at various ages. 
Immunization  with Autologouz  or Syngeneic  Tumor Cdls.--In  the experiments designed to 
investigate whether it is possible to induce a  transplant immunity in the primary tumor- 
bearing animals the procedure was similar to that previously used in experiments with methyl- 
cholanthrene-induced sarcomas  (9). Mter extirpation the primary tumor was dissected free 
under sterile conditions, and part of the tumor was trypsinized. Known numbers of trypan 
blue unstained tumor cells (10) were inoculated subcutaneously into syngeneie preirradiated 
recipients, in order to determine the cell number necessary for progressive tumor growth in 
100% of irradiated controls (=  Dmx)  and in order to keep the tumor in passage. Another 
part of the tumor was used for immunization. 0.1  cc of an irradiated  (8000 R)  crude cell 
suspension was inoculated subcutaneously into the autochthonous host and 5  to  I0 sham- 
operated previously untreated syngeneic mice.  The inoculations of X-irradiated cells were 
repeated three times at biweekly intervals, using tumor material from a  frozen part of the 
original tumor or from the first passage of this tumor. 
Transplantation  tests  were  performed  by  subcutaneous  inoculation  of  mechanically 
prepared or trypsinized cell suspensions. 
The transplantability of primary tumors to  the autochthonous hosts immediately after 
extirpation of the tumors in question, was tested with the use of a crude cell suspension pre- 
pared by thorough mincing of the tumor tissue in balanced salt solution and filtration through 
double gauze, whereafter the suspension was inoculated subcutaneously undiluted or diluted 
1:10 or  1:100, respectively. In this way  an attempt was made to inoculate a  suitable test 
dose, as there was no opportunity to determine the exact minimum cell dose necessary for 
progressive growth in untreated controls (= Dm). The test cell dose was deposited at a  site 
distant from the recently operated area in order to avoid confusion with a  recurrence of the 
original tumor.  Mice presenting such recurrences were  omitted.  Previously untreated  syn- NILS  JONSSON AND HANS OLO~F SJOGREN  489 
geneic mice were sham operated in parallel with the autochthonous hosts and served as con- 
trois. 
As it  seemed also  desirable  to use  critically  determined test  cell  doses and to use recipients 
that had recovered from the operation with certainty,  other experiments included the same 
type of recipients,  inoculated at various times after  the extirpation  with known numbers of 
trypan blue unstained tumor cells.  The test  tumors were previously examined syngeneic or 
autologous Rous tumors with known Dm  and with established  specific  transplantation  anti- 
genieity  (3).  Litter  mates of  the  experimental animals,  inoculated  with a suspension of  normal 
chicken tissue  (liver,  skeletal  muscle) when newborn and sham-operated in parallel  with the 
tumor-bearing  mice,  were used as controls. 
When testing  rcdpients,  immunized with irradiated  autochthonous tumor cells  after  ex- 
tirpation  of the primary tumor, known numbers of trypsinized  tumor cells  from the autoch- 
thonous tumor or  a syngencic tumor with establishcd  antigenicity  were inoculated. 
Animals, developing no primary tumors within 2 months after  recdving an inoculation  of 
Rous chicken sarcoma tissue  when newborn, were tested  with known numbers of tryp~ini~l 
syngeneic tumor cells  deriving  from tumors with established  antigenicity.  Litter  mates inocu- 
lated  with normal chicken tissue  or syngeneic mice, inoculated as adults  with 0.25 cc of the 
same Rous chicken sarcoma suspension,  were used as controls. 
M~se serum was obtained from blood collected  by puncturing  the  retroorbital  sinus 
with a glass capillary. 
Antidral  anffbodles were  assayed  according  to  the  focus-neutralizing  technique  of 
Rubin et al. (11, 12) as described previously (3). Each test included 2 mouse serum dilutions 
(1:2, 1:3, or 1:$, depending upon the amount of serum available, and 1:20 or 1:25, respec- 
tively). Chicken anti-RSV-SR serum served as control serum. 
Irradiation Procedures.--Groups of mice received total body X-irradiation 24 hr prior to 
the test in doses of 300 R to animals up to 2 wk of age and 350 to 400 R to older animals. Tu- 
mor cells were irradiated with a dose of 8000 R. X-rays were generated at 200 kv, 15 ma and 
filtered by 0.5 mm AI +  0.5 mm Cu for the mice and by 1 mm AI for  the tumor cells. 
The test animals were  inspected once  a  week.  Developing  tumors  were  measured  by 
caliper and the geometrical mean of 3 diameters was estimated. 
RESULTS 
Specific  Transplantation  Immunity  of Mice  Pretreated  with  RSV-SR  when 
Newborn  but  Developing  No  Primary  Rous  Sarcornas.--Known  numbers  of 
trypsinized Rous tumor  cells were inoculated into  the following categories of 
genetically compatible recipients: (a) mice inoculated when newborn with 0.05 
ml of an 1:5 suspension of Rous chicken sarcoma (RSV-SR), but developing no 
palpable primary tumors before the test (2 to 5 months); (b) litter mates of the 
previous group of mice, pretreated when newborn with a subcutaneous inocula- 
tion  of normal  chicken tissue;  and,  as controls  (c)  mice pretreated as adults 
with 4 to 6 allografts of Rous mouse sarcomas with known specific antigenicity; 
and (d) untreated mice. The mice were either unirradiated or preirradiated 24 
hr prior to test. The  test tumor cell doses were  given subcutaneously on  the 
abdomen or the breast in order to avoid confusion with later appearing primary 
tumors. The doses given were chosen on the basis of previously determined cell 
doses required by each test tumor to grow progressively in 100 %  of untreated 
mice, unirradiated  (= Din)  or preirradiated (= Dmx). 
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TABLE I 
Results of Isotransplantation of 5 Different Rous Mouse Sarcomas into Recipients, Inoculated 
when Newborn with RSV-SR, but Developing no Primary  Tumors 
Test 
tumor 
RCB 
RSC 
RSC 
RDAA 
RDAA 
RDAB 
RSBE 
Mouse strain  Cell dose 
A.  CA  l& 
10  ~ 
104 
A  X  CBA  104 
105 
A X  CBA  i0' 
lo` 
A X  DBA/2  5 
5 
5 
A X  DBA/2  5 
5 
X  102 
X  10  3 
X  10' 
Whole body 
X-irradi- 
A  X  DBA/2 
A X  CBA 
total (unirradiated) 
total (irradiated) 
400 
400 
375 
375 
375 
375 
375 
No. of takes~ 
ation*  Un- 
treated 
controls 
R 
--  4/4 
--  5/5 
5/5 
4/4 
5/5 
4/4 
4/4 
Inoculated 
when new- 
born with 
normal 
chicken 
tissue 
3/6 
5/5 
6/6 
4/4 
3/3 
3/3 
1/4 
5/5 
X  10  ~  400  --  9/10 
X  10  s  400  --  5/5 
i04  350  --  19/19 
5  X  103  400  5/5  3/3 
5  X  104  400  --  2/2 
Dm[[  --  4/4  3/6 
10  X  Dm  --  5/5  5/5 
100  X  Dm  --  --  -- 
Dmx[[  350--400  18/18  44/45 
10  X  Dmx  350--400  9/9  19/19 
100  X  Dmx  350--400  --  -- 
Inoculated 
when new- 
born with 
Rous chicken 
sarcoma 
suspeoslon 
o15 
2/4 
3/5 
10/19§ 
s/8§ 
3/4§ 
2/3§ 
2/5 
3/5 
3/3 
5/12 
7/7§ 
9/14§ 
6/9§ 
6/6 
0/5 
2/4 
3/5 
35/63 
23/29 
3/3 
Allo- 
srafted 
with Rou~ 
tumor 
3/4§ 
2/4 
3/8 
1/2 
9/18 
* 24 hr prior to test. 
:~ Figures denote number of mice with progressively growing tumors over total number 
inoculated. 
§ Means prolonged latency period and slower tumor growth than in the control groups. 
[[ Means the approximate minimum cell number required for progressive tumor growth in 
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Only mice developing no primary tumors during the test period are included in 
the table. Unirradiated mice, pretreated with normal chicken tissue show some 
resistance, which cannot be detected after preirradiation and thus probably is 
nonspecific. Recipients pretreated when newborn with RSV-SR show a clear- 
cut immunity to cell doses, corresponding to Dm and 10 x Dm (I)mx and 10 x 
Dmx, respectively). The immunity is expressed as a reduced frequency of takes 
in comparison with mice pretreated with normal tissue. The resistance is not 
abolished by whole body X-irradiation prior to the challenge. The summarized 
results reveal a  highly significant difference between preirradiated mice pre- 
treated with Rous chicken sarcoma and mice pretreated with normal chicken 
tissue (X  ~ for the ])mx dose =  21.72;  P  <  0.001~'-~). The controls allografted 
with Rous tumors showed the expected immunity. 
The resistance of the RSV-SR pretreated mice is apparent not only from the 
take figures but also from the tumor growth curves  (Figs.  1 a  and  1 b). The 
figure shows  the prolonged  latency period  and  slower  tumor growth  of  the 
RSV-SR  pretreated  mice  in  comparison  to  animals pretreated  with  normal 
chicken tissue. The resistance is thus of a higher magnitude than that demon- 
strated in the above table. 
In another series of experiments mice, pretreated as adults with a subcutane- 
ous inoculation of 0.25  cc  of the same Rous chicken sarcoma suspension as 
newborn  mice  received,  were  tested  parallelly  for  specific  transplantation 
immunity. The results are summarized in Table II, in which two different time 
intervals between the RSV-SR inoculations and the tests are noted. Also the 
recipients pretreated with RSV-SR as adults were in one experiment (test tumor 
RS57A)  found to be resistant even after preirradiation before the test. This 
resistance was demonstrated 2 wk after the RSV-SR inoculation, while simul- 
taneously tested mice, infected 4 wk previously, were not resistant. No trans- 
plantation immunity could be demonstrated in the other 3 experiments with 
preirradiated recipients. The isograft resistance of mice inoculated with RSV-SR 
when newborn was clearly demonstrable also in these experiments, although it 
was not as strong as in the above mentioned series of experiments (X  2 =  5.74, 
calculated for the Dmx dose in comparison with untreated controls; 0.02  :> 
_P > 0.01=). 
Transplantation  Immunity  Tests in  Primary  Turrwr-Bearing Mice  after 
Extirpation of the Primary  Turtwr.---One  series of experiments was performed 
immediately after the  operation.  Mter  tumor extirpation under ether anes- 
thesia, 0.1 cc of the crude tumor cell suspension, undiluted or diluted 1:10 or 
1:100,  was  inoculated  subcutaneously into  the  autochthonous host  and  to 
syngeneic  control  mice,  sham  operated  in  parallel  with  the  tumor-bearing 
mouse. The controls were divided into groups of 3 to 5 animals for the different 
tumor  cell dilutions.  In  some  experiments  the  tumors  did not  grow  in  the 
largest cell doses given and were lost. In acceptable experiments (11  tumors) 492  ROUS  SARCOMA VIRUS  TUMORIGENESIS 
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tive groups. NILS  JONSSON  AND  HANS  OLOF  SJOGREN  493 
the approximate Dm could be determined for each tumor at the end of the obser- 
vation period on the basis of the appearance and growth of the test tumors in 
the controls. The doses given to the autochthonous hosts correspond to 0.1  X 
TABLE II 
Results of lsotransplantation of g Differen~ Rous Tumors into Mice Pretreated wken Newborn or 
Adult with RS V..S  R 
Test 
tumor 
RSC 
RS57A 
RS57A 
RSC 
RSC 
RSC 
Total (unirradiated) 
Mouse strain  Cell dose 
A/Sn  5  X  10  s 
5  X  104 
A  X  C57BL  5  X  10  ~ 
A  X  C57BL[  5  X  10  s 
A/Sn  5  X  10  s 
5×  10  ~ 
A  X  CBA  5  X  10  s 
sx  lO  ~ 
A  X  C57BL  5  X 
5X 
0,1X 
Dm 
Total (irradiated) 
lOs 
10  4 
Dm 
No. of takes$ 
Whole body  Inoculated when  Inoculated when 
X-irradi-  adult with Rous  newborn with Rom 
ation*  Un-  chicken sarcoma  chicken sarcoma 
treated  suspension  suspension 
controls 
0, 1 X  Dmx  300-350 
Dmx  300-350 
10 X  Dmx  300-350 
<2wk§  >4wk§  __.2wk§  >4wk§ 
R 
--  3/4  --  s/8  --  o/4 
--  3/3  --  5/5  --  0/3 
--  5/5  0/5  2/4  0/4  0/2 
300-35011  5/5  1/4  4/4  0/3  0/1 
300-350[[  6/6  8/8  8/8  9/9  7/11 
300-3501l  5/5  5/5  --  8/8  6/6 
300-3501]  6/10  6/10  9/10  12/12  16/19 
3O0-350H  4/4  --  --  4/4  10/11 
3¢x~-350H  --  3/5  --  2/6  0/3 
300-3501]  5/5  5/5  --  4/7  0/2 
--  3/4  --  5/8  --  0/4 
--  8/8  0/5  7/9  0/4  o/s 
6/10  9/15  9/10  14/18  16/22 
20/20  14/17  12/12  17/23  17/25 
5/5  5/5  --  8/8  6/6 
* 24 hr prior to test. 
~t Figures denote number  of mice with progressively growing tumors over total number 
inoculated. 
§ Interval between RSV-SR inoculation and test. 
II 3o0 R  given to mice 2 wk of age, 350 R  to older animals. 
Dm,  Dm and  10  X  Dm,  respectively. The results are grouped in Table III 
according to these cell doses. Except in 2 cases no transplantation immunity 
could be demonstrated in the primary autochthonous hosts. The latency periods 
and tumor growth curves in these animals did not differ from what was observed 494  ROIYS  SARCOMA  VIRUS  TUMORIGENESIS 
in the controls given the same cell dose. Two of the tumors, randomly chosen, 
were  tested  for  specific transplantation  antigenicity by isografting  to  mice, 
previously allografted with other Rous tumors, and for the presence of the viral 
genome by inoculation into chickens; both the tumors contained the RSV-SR 
and were specifically antigenic as well. 
One of the resistant autochthonous hosts proved resistant also at a repeated 
transplantation test. 
In another series of experiments known numbers of tumor cells deriving from 
Rous tumors with previously determined Dm and Dmx doses were used to test 
for transplantation immunity at different times subsequent to the extirpation of 
TABLE III 
Results of Autotransptantation of 11 Primary Rou* Tumors to the Operated, 
Autochthonous Hosts* 
Cell dose 
0, 01 X Dm 
0,1X Dm 
Dm 
0, 01 X Dm 
0,1X Dm 
Dm 
0, 1 X  Dm 
I)m 
10 X  Dm 
No. of takes$ 
Operated  autochthonous  hosts 
3/3 
3/5 
3/3 
Sham-operated  controls 
0/5 
4/9 
3/3 
2/3 
12/17 
16/18 
2/6 
7/7 
11/11 
* The results are grouped according to the cell dose given to the autochthonous hosts. 
:~ Figures denote number of mice with progressively growing tumors over total number 
inoculated. 
the primary tumors. In order to detect a possible tolerance against the specific 
transplantation antigens the experiments also included low cell doses (0.01  X 
I)m and 0.1  X  Din). The Dm (Dmx) and 10 X  Dm (10 X  Dmx) were given to 
unirradiated and preirradiated recipients in order to detect a  possible trans- 
plantation resistance. The results collected in Table IV and the rate of tumor 
growth  demonstrate  no  significant difference between  the  operated primary 
tumor-bearing mice  on  one hand  and  untreated  controls  or  sham-operated 
controls, pretreated with  normal  chicken tissue  on  the  other.  A  very weak 
resistance of the operated, primary tumor hosts cannot be excluded, however, 
since the frequency of takes was slightly reduced in most experiments. In the 
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10 X  Dm dose of its own autologous tumor. No increased frequency of takes 
was noted for the lower cell doses in mice with extirpated primary tumors. Thus, 
there was no indication of a specific tolerance. 
Tests  for  Transplantation  Immunity  in  Operated Primary  Tumor-Bearing 
Mice Subsequent to Pretreatment with Irradiated Autologous or Syngeneic  Tumor 
Cells.--Since  the  specific transplantation  antigen(s)  of Rous mouse sarcoma 
TABLE  IV 
Results of lsotransplantation of 4 Different Rous Mouse Tumors into Mice after Extirpation of 
Primary Tumors 
No. of takes~; 
Whole  Controls  inocu-  Interval  body  Cell  dose  lated  when 
Test  tumor  exfirpa- X-irradi-  Un-  newborn  with 
tion-test  ation*  treated  normal chicken 
controls  tissue. Sham 
operated. 
~k  R 
RSC  0  --  0, O1 X  Dm  0/5 
0, 1 X  Dm  2/10 
RWE  3  --  Dm  4/4 
10 X  Dm  4/4 
RSC  2-4  --  (0, 1-0, 2) X  10/15 
Dm 
RCB  5  --  Dm  3/3 
10 X  Dm  5/5 
RSC  3-7  375  Dmx  4/4 
10 X  Dmx  5/5 
RDAA  3-5  375  Dmx  4/4 
10 X  Dmx  4/4 
Total (unir-  0-5  --  0, 01 X  Dm  0/5 
radiated)  (0, 1-0, 2) X  12/25 
Dm 
Dm  7/7 
10 X  Dm  9/9 
Total (irradi-  3-7  375  Dmx  8/8 
ated)  10 X  Dmx  9/9 
O1.~.  rated 
primary 
tumor-bearing 
recipients 
I/4 
--  0/2 
--  0/1 
8/15  3/9 
--  ill 
111  ill 
414  314 
414  313 
3/3  3/4 
sis 
1/4 
8/15  3/11 
--  1/1 
1/1  1/2 
7/7  6/8 
9/9  3/3 
* 24  hr  prior  to test. 
Figures denote number of mice 
inoculated. 
with progressively  growing tumors over total  number TABLE V 
Results of Auto- and Isotransplantation of 12 Different Rous Mouse Sarcomas to Operated 
Primary Tumor-Bearing and Immunized Recipient, 
Test tumor 
RDAA (a) 
RDAB (a) 
RSS7A (a) 
RSC (s) 
RSZ (a) 
RDAB (a) 
RSBE (a) 
RSBF (a) 
RS57C  (a) 
RSS7D  (a) 
RCH (a) 
RWHB (a) 
RWHD (a) 
Whole 
Mouse strain  body  X-irradi-  Cell  dose 
ation*  Untreated 
controls 
R 
A X  DBA/2  --  103  S/5 
lo,  s/s 
A )< DBA/2  --  10  4  4/5 
10  ~  5/5 
A x  CSTBL  --  I~  a/s 
aos  s/s 
A/Sn  350  5 X  los  5/5 
A/Sn  350  102  4/5 
los  s/s 
A X  DBA/2  400  los  8/8 
105  5/5 
A X  CBA  400  5 X  los  4/4 
5 X  104  5/5 
A X  CBA  400  5 X  los  3/4 
5 X  los  4/4 
A X  C57BL  350  los  5/5 
105  4/4 
A X  C57BL  350  108  5/5 
los  5/5 
C3H  350  5 X  10  ~  5/5 
A.SW X  C3H  400  5 X  los  5/5 
5 ×  lO  4  5/5 
A.SW X  C3H  400  los  5/5 
l0  s  4/4 
No. of  takes~: 
Total]l  (unirradiated)  --  [ Dm  10/10 
10 X  Dm  5/5 
Total[[  (preirradiated)  350-40C  Dmx  27/27 
10 X  Dmx  23/23 
Sham~perated  Operated, p~- 
cont~Is pre-  mary tumor- 
treated win  beating mice 
•  e test Rous  pretreated win 
tumor isografts  ~e test Rous]tu 
(X 8~0 R)  mor (X 8000 R' 
0/s  i/I 
o/s  o/1 
2IS  Oll 
2/5  0/1 
o/s  o/1 
--  0/1 
0/6 
1/6  1/1 
0/5 
3/S  1/~ 
0/4 
o/s  o/1 
o/s  1/1§ 
2/4§  0/1 
o/5 
3/s§  o/1 
4/5§  1/1§ 
2/10  0/2 
0/5  1/1 
8/26  3/5 
a, autologous test tumor; s, syngeneic test tumor. 
* 24 hr prior to  test. 
:~ Figures denote number of mice with progressively growing tumors over  total  number 
inoculated. 
§ Means prolonged latency period and slower tumor growth than in untreated controls. 
]] In the summaries only mice given the same cell dose  as the  respective  autoehthonous 
host  are  included. 
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FIGS. 2 a and 2 b. Growth of 103 cells (--- 10 X  Dmx) from 1st transfer generation of Rous 
tumor RWHD and 104 cells (---- 10 X  Dmx) from 1st transfer generation of tumor RS57D, 
respectively, after tr-Ansplantafion  ~nto prelrradiated syngendc m;ce, untreated  (t2), or sham 
operated and pretreated with irradiated tumor material  (R) as well into the operated  auto- 
chthonous  hats,  parallelly pretreated  with  irradiated  tumor  material  (A).  Eadl curve re- 
presents tumor growth in one recipient. 498  ROUS  SARCOMA  VIRUS  TUMORIGENESIS 
cells is  radioresistant  (3)  irradiated  tumor  cells were used for  immunization. 
Table V  summarizes the results of the transplantation tests performed on the 
operated autochthonous  hosts  and  sham-operated syngeneic mice,  pretreated 
in  parallel with  irradiated tumor  material.  In most  experiments  the  original 
tumors  were  used  both  for  immunization  and  testing,  but  in  one  case  the 
tumor was lost and replaced by a syngeneic Rous tumor of known antigenicity. 
Tests were performed with  15  autochthonous  hosts,  of which 3,  however, had 
recurrences of the original tumor and were excluded. In both the experiments 
performed  on  unirradiated  recipients,  in  which  the  Dm  dose  was  used  for 
TABLE VI 
RSV-SR-Neutralizing Activity in Sera of Mice used in the Transplantation  Tests 
Pretreatment 
RSV-SR when newborn 
No development of primary tumors 
RSV-SR when newborn 
Primary tumor extirpated 
RSV-SR when newborn 
Primary tumor extirpated 
[mmunization  with  irradiated  autologous 
or syngeneic tumor cells 
=ontrol  mice,  immunized  with  irradiated 
syngeneic tumor cells 
RSV-SR when adult 
Results of trans- 
plantation tests 
Resistant* 
Nonresistant  * 
Resistant 
Nonresistant 
Resistant  * 
Nonresistant* 
Resistant* 
Resistant* 
Nonresistant  * 
No. of tested serawith titer 
<1:2-1:5  1:2-1:5  ~1:20 
18  --  -- 
10  --  2 
2  --  -- 
3  1  -- 
3  I  -- 
7  --  -- 
6  --  -- 
* Preirradiated mice. 
testing,  the autochthonous  hosts were resistant as well as the syngeneic mice 
pretreated in parallel, while with the third tumor no resistance could be shown 
against  the  l0  X  Dm  dose.  Four  out  of 5  immunized  autochthonous  hosts, 
preirradiated before the test challenge, were also completely resistant against 
the I)mx dose,  while in one animal no resistance was demonstrable although 
the  pretreated  syngeneic  mice  were  resistant.  A  complete  resistance  of  the 
preirradiated autochthonous  hosts  against  the  10  X  Dmx  dose  was  also de- 
monstrable in 2 out of 5 animals. In two other experiments the appearing test 
tumors  showed  a  prolonged latency period and  slower  tumor  growth  in  the 
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untreated controls (Figs.  2 a  and 2 b).  In the remaining case the pretreated 
syngeneic mice but not the autochthonous host were resistant against the 10 
X  Dmx dose. 
Tests for Virus-Neutralizing Activity in the Sera of Mice Used in the Trans- 
plantation  Experiments.--The results are summarized in Table VI. Only sera of 
preirradiated mice are included, with the exception of the group tested directly 
after extirpation of the primary tumors, in which no preirradiafion was per- 
formed.  Among  the  mice  resistant  against  tumor  induction  after  RSV-SR 
inoculation in the neonatal period, only 2 developed neutralizing activity, and 
none of these animals revealed any isograft resistance. The other 28 sera tested 
contained no virus-neutralizing activity irrespective of whether the mice were 
transplantation resistant or not. One of the mice developing primary tumors had 
a fiter of 1:3 and was not resistant on autografting. The other 5 sera obtained 
from mice with primary tumors were negative. Three out of 4 operated primary 
tumor-bearing mice as well as syngeneic controls, pretreated with irradiated 
tumor cells had no demonstrable virus-neutralizing activity. Nor could such 
activity be found after RSV-SR inoculation into adult animals, as was pre- 
viously found (3). 
DISCUSSION 
The present investigation fully confirms the results of preliminary experi- 
ments (8) that mice inoculated during the first few days of life with living RSV- 
SR chicken sarcoma cells and remaining free from primary tumors thereafter, 
are specifically immune to Rous sarcoma isografting. That an immunization 
against possible specific chicken tumor antigens is of no importance for induc- 
tion of this immunity is indicated by the finding that mice treated with one dose 
of Rous chicken sarcoma cells when newborn develop a stronger immunity than 
animals treated, even repeatedly, as adults. Adult mice would be expected to 
react more vigorously than newborns if the antigens were fully expressed in the 
inoculated chicken sarcoma cells. Therefore it seems more likely that the specific 
transplantation immunity is induced by Rous virus released from the inoculated 
chicken sarcoma cells.  A  specific  transplantation immunity against polyoma 
tumors has previously been  demonstrated in mice inoculated with  polyoma 
virus when newborn without developing any primary tumors (5,  13). On the 
other hand inoculation of SV40 virus into newborn hamsters does not induce 
any isograft immunity against SV40-induced tumors irrespective of whether 
primary tumors later develop or not (7). 
The differences among the mentioned viruses in  their capacity to  induce 
transplantation immunity might be  due to  time  factors. Xenografted Rous 
chicken sarcoma cells are known to survive several days in newborn mice and 
rats  (14),  permitting  a  prolonged  release  of virus.  This might  lead  to  the 
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at  a  time  when  the  mice  have  reached immunological competence to  react 
against  these  antigen(s).  The lack of immunization of hamsters  against  the 
specific transplantation antigen(s) of SV40 tumors after inoculation of a  cell- 
free  SV40  virus  preparation,  might  be  due  to  the  induction  of  the  specific 
antigen(s) in an insufficient number of cells to give immunization. A prolonged 
virus infection comparable to the RSV-SR infection after inoculation of living 
chicken Rous sarcoma cells might very well give rise to an immunity also in the 
SV40 system. The immunity demonstrable after a repeated SV40 virus inocula- 
tion (7) might be explained in this way. Finally, in the case of polyoma virus, 
an active multiplication until the time of immunological maturation,  is indi- 
cated  by the  high  titers  of hemaggiufinating  antibodies  in  the  sera  of mice 
which have been inoculated with polyoma virus when newborn (13). Thus, it is 
understandable that a specific immunization can take place against the poly- 
oma specific tumor antigen. 
Tests for RSV-SR-neutralizing antibodies in  the  sera of newborn-infected 
mice gave negative results in most cases. This cannot be taken as an indication 
of a specific tolerance to the RSV-SR antigen or the absence of exposure to the 
viral antigen  at  an  immunologically mature  age,  since it has  been reported 
previously that even repeated RSV-SR doses given to adult, immunologically 
competent mice regularly do not induce any detectable antiviral antibodies (3). 
The antiviral activity demonstrated in a few sera of newborn infected mice 
indicated that at least in some cases the virus persisted in the animal up to the 
time when immunological competence had developed. Since positive titers were 
found in mice developing primary tumors and in the tumor negative ones as 
well,  it  seems  to  be  no  correlation between  the  detected antiviral  immune 
response and tumor development. 
As has been reported previously (3) there is no positive correlation between 
the occurrence of antiviral serum activity and isograft immunity and thus no 
indication of an identity between the antigens of the mature virus particle and 
the transplantation antigen(s). 
The rather strong isograft immunity of mice, resistant to RSV-SR primary 
tumor induction raised the question of the immunological status of the mice 
which  are  sensitive to  tumor induction.  Are  also  these  animals  immunized 
against the RSV-SR specific transplantation antigen(s) or is the development 
of primary tumors linked with a  tolerance  to these antigens  developed as a 
result of antigen exposure during the period of immunological immaturity? 
In order to study these questions the primary tumors had to be extirpated 
since primary Rous sarcomas usually grow rapidly and would otherwise have 
interfered with the experiments performed. Tests for transplantation immunity 
against autologous tumor cells, performed immediately after the extirpation of 
the primary sarcomas gave no indication of any resistance in 9 of the 11 tested 
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The test cell doses must be approximate in this type of experiments and it is 
always difficult to rule out completely the possibility that the extirpation of the 
tumor might affect the animal differently from the sham operation in some 
respects.  Therefore well known syngeneic test tumors were used for further 
tests at various intervals after operation. No clear-cut transplantation immunity 
could be demonstrated, neither in unirradiated nor in preirradiated operated 
mice although a  very weak resistance could not be excluded. Nor could any 
tolerance to the transplantation antigen(s) in the form of increased frequency of 
takes with low test cell doses be demonstrated. It might be objected that toler- 
ance could have subsided after removal of the antigenic stimulus at operation, 
but at least in the first test in Table IV (test tumor RSC)  this could not be 
the case, since the test was performed immediately after the extirpation. 
Also these results, obtained with mice which had developed primary Rous 
sarcomas are different from those reported for SV40 tumors. Deichman et al. 
(7), found that hamsters bearing primary SV40 tumors were immune to estab- 
lished SV40 tumor challenge, obviously due to the immunizing capacity of the 
primary tumor, while no immunity or tolerance was demonstrable during the 
induction period. It is possible that the development of primary Rous tumors is 
connected with a  resistance too weak to be  detected in  the  transplantation 
tests.  The  possible  role  of an  enhancement phenomenon as  a  result  of the 
presence of large amounts of humoral antibodies in the primary tumor host 
should be  taken into account. The present experiments permit no conclusion 
on this point.  Finally, an  unspecific  depression  of  the  immune reaction  of 
the primary tumor host, e.g., by toxic products from the rather large primary 
tumors, might also be considered as an explanation for the absence of any clear 
immunity. 
Similar tests for specific  immunity against antigenic, methylcholanthrene- 
induced mouse sarcomas in the operated autochthonous hosts have also given 
negative results in pre]imlnary experiments (15). 
The results of serial treatment of operated, primary tumor-bearing hosts with 
irradiated autologous or syngeneic tumor material clearly show that it is possi- 
ble  to  immunize  these  animals  against  the  tumor-specific  transplantation 
antigen(s).  This  is in  accordance with  the  previous  finding that  a  state  of 
isograft immunity can be  built up  against methylcholanthrene-induced sar- 
comas by a similar treatment with irradiated autologous tumor cells  (9).  The 
results fit well also with  the  absence  of any demonstrable  tolerance to  the 
specific  cellular antigen(s)  in  the primary tumor hosts when tested without 
postoperative immunization. If it existed, such a  tolerance would have been 
expected to be maintained by the pretreatment as would probably an immuno- 
logical enhancement, which thus also seems less likely. However,  a  possible 
partial tolerance might be shifted into immunity by removal of the tumor and 
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existence of a  very weak resistance, not detectable in direct transplantation 
tests, but strengthened by the pretreatment. 
The finding (7,  16)  that SV40 tumorigenesis can be prevented in hamsters 
infected when newborn by pretreatment during the latency period with SVdO 
virus or SV40 tumor cells indicates that tumor induction occurs in the absence 
of any tolerance in that system. 
The  successful  immunization  of  autochthonous  hosts  against  the  Rous 
mouse tumor antigen(s)  also definitely rules out the possibility that isoanti- 
genic heterozygosis might have been responsible for the allo- or isograft-induced 
transplantation immunity of earlier experiments (2, 3). 
It is tempting to conclude from the results presented that the development 
of primary sarcomas is prevented in some mice that have been infected with 
RSV-SR  when  newborn,  because  of  a  successful immunization against  the 
RSV-SR  specific  transplantation  antigen(s).  Whether  the  weak  or  lacking 
immune response of mice sensitive to tumor induction is a  cause or a  conse- 
quence of the tumor development cannot be definitely settled at present. The 
fact that these animals could be immunized indicates that there is no primary 
immunological defect of the hosts and that the primary hosts are probably not 
immunologicaUy tolerant to the RSV-SR specific transplantation antigen(s). 
SUMMARY 
Tests for transplantation immunity and for the occurrence of virus-neutral- 
izing  serum antibodies were performed on mice, inoculated when newborn with 
the Schmidt-Ruppin strain  of Rous sarcoma virus (RSV-SR). Mice developing 
no palpable primary sarcomas showed a clear-cut resistance against the iso- 
grafting of established specifically  antigenic Rous  tumors. Transplantation 
tests  performed on primary tumor hosts  after  extirpation  of  the tumors revealed 
neither any clear-cut immunity nor tolerance to the specific  transplantation 
antigen(s).  Serial  pretreatment of operated primary tumor animals with irradi- 
ated autologous or syngeneic tumor cells  resulted  in a clear-cut  transplantation 
immunity. Virus-neutralizlng activity  was only found in a few sera from new- 
born infected mice, and in these cases there was no positive correlation  with 
the transplantation immunity. 
It  seems  probable that  a successful  immunization against the RSV-SR specific 
transplantation antigen(s) prevents the  development of primary tumors. There 
is  no  indication  of  any tolerance  to this  antigen  in  connection  with the  induction 
of  primary tumors. 
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